Clinical Trials Logo

Treatment Refractory clinical trials

View clinical trials related to Treatment Refractory.

Filter by:
  • None
  • Page 1

NCT ID: NCT01251055 Completed - Schizophrenia Clinical Trials

GlyT-1 Inhibitor Treatment for Refractory Schizophrenia

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The etiology of schizophrenia remains unclear In recent one decade, hypofunction of N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia. Hence, enhancing NMDA neurotransmission was considered as a new approach for schizophrenia treatment. To date, refractory schizophrenia (particularly clozapine-resistant) is still a difficult clinical issue. However, the effect of NMDA treatment in refractory schizophrenia is still unknown. Therefore, the primary goal of this study is to investigate the efficacy and safety of NMDA adjuvant therapy in refractory schizophrenia, and to identify the predictors for treatment response to NMDA enhancers.